about
Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidneyCloning and characterization of a fourth human somatostatin receptorMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursClinical utility of lanreotide AutogelĀ® in gastroenteropancreatic neuroendocrine tumorsTreatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatinProgrammed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatinSomatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues.Biology of pancreatic cancerGene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenograftsInhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanismsDominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.Somatostatin receptors in the gastrointestinal tract in health and diseaseTreatment of hepatocellular carcinoma with octreotide: a randomised controlled studyClinical response to Auron Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case reportSynthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancerA randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude miceMicroencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.Analysis of somatostatin receptor subtype mRNA expression in human breast cancer.Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.Effect of octreotide on cell-cycle kinetics and serum carcinoembryonic antigen level in hepatic metastases of colonic adenocarcinoma.Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.Update on management of midgut neuroendocrine tumors.Primary carcinoid tumour of the kidney: a review of the literature.A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity.Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumorsSomatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.Somatostatin therapy for glomus tumors: a report of two cases.Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.
P2860
Q24337883-1F8B51B8-795C-4D26-877F-9C35DC080A55Q24563011-A7C1C6CB-6B05-46D5-9820-15936F2B7562Q26751659-9E3F5D4C-936A-4A55-ADD7-AC1BA12A5350Q28069632-1518BB52-E600-4E2E-BCA6-A8F9B594E8A5Q33506131-D0FDB6F0-1E05-43B1-95E7-CFA48AA0968BQ33753449-7897F65C-6427-41E3-9996-BAA545F17399Q33771581-6C8E403E-9502-4734-BE92-EA7E66330590Q33841242-2E1D59B8-7F80-4E5F-BF1A-FDA621878D84Q33844684-ED550D85-3539-4B20-AF4E-17A3B3DD83D8Q34378050-0101C367-46E6-426C-9840-73594A703F9CQ34394264-6166A249-198D-4853-9838-001A8DAB056FQ34605758-D6039874-9327-4223-A9EA-93B6088FB663Q34634036-3471FB29-213D-49DD-8E2B-C22FD07A4050Q35098025-A97C778F-E27D-4255-8F9C-2499BBC05552Q35106579-1B1AEF8D-DAC6-48F1-942C-D773F6EB16C4Q35241625-432AD76C-80D9-4A2D-BF80-EBA3ED077BE6Q35349653-4A748C2F-16F1-4696-A5BE-019305AE13AAQ35478306-AC4806CD-8FBC-4885-80D9-313A8DE06EAEQ35973711-48173908-C532-4BD8-AA8D-2881BE9FED02Q35992853-930573C3-AD4B-47DE-BCC0-31034550AC7EQ35993786-EAC40FB5-9CDF-4072-9159-D61C132D17FBQ36079892-B48E8B35-79BF-4C74-BE7E-A2E056388E41Q36080188-8C740B87-93EC-47D9-A997-F360B789F623Q36114875-C7868274-7E92-4CA4-A13E-545B4966F085Q36116487-1A449B46-0EBD-43A0-8F35-4C87892786E5Q36295053-14C8C150-9830-4B93-8CA8-F697CEA26DBBQ36566036-812070F5-2546-40E0-ACB1-8787D5F4960CQ36618041-7CE8DEE8-AB9B-4E66-B3E8-D130C476788AQ36619058-332C6F35-EB37-459E-8701-4A2C2E702032Q36712564-EBE65379-58AA-48FF-8366-01C02538F7FDQ36916282-7839A594-0BBD-42F9-BEDD-CD7AEE8578E5Q37025143-68B98E08-38CC-4520-94B6-1588FFD40BE9Q37127276-3BAF377D-CCB3-4556-8CA1-C93EEE7A8D4FQ37242234-E283A841-2FE5-4C3C-9C7F-E972AE56BBBEQ37412449-0516C83C-3E20-4AF8-ADB9-A9220F89084DQ37564373-D8863A68-FE3C-4BBC-A8A1-BFC989D54309Q38302368-D68FE0D6-A11F-44EE-8C2C-0C4DE01A3841Q39762535-E00A85B3-BC7F-4C9C-834E-37D8B4CEAD6CQ39763546-24C205C4-CD6C-46CF-A365-AB24D23869CDQ39842258-B4FC1806-D738-4DC7-9B6E-C0375EA55214
P2860
description
1988 nĆ® lÅ«n-bĆ»n
@nan
1988幓ć®č«ę
@ja
1988幓č«ę
@yue
1988幓č«ę
@zh-hant
1988幓č«ę
@zh-hk
1988幓č«ę
@zh-mo
1988幓č«ę
@zh-tw
1988幓č®ŗę
@wuu
1988幓č®ŗę
@zh
1988幓č®ŗę
@zh-cn
name
Oncological applications of somatostatin analogues.
@en
Oncological applications of somatostatin analogues.
@nl
type
label
Oncological applications of somatostatin analogues.
@en
Oncological applications of somatostatin analogues.
@nl
prefLabel
Oncological applications of somatostatin analogues.
@en
Oncological applications of somatostatin analogues.
@nl
P1433
P1476
Oncological applications of somatostatin analogues.
@en
P304
P407
P433
P577
1988-12-01T00:00:00Z